ERNA

Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA 101 in ovarian cancer.read more...

Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period.

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

Ernexa’s ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models.

Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance...

From billion-dollar AI buildouts to preclinical cancer breakthroughs and other milestones, investors are being forced to reassess where the next wave of outsized returns could emerge. $ERNA, $KBLB, $EVC, $NVDA, $GLW, $AHMA

The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer Cellipont Bioservices and Ernexa Therapeutics...

As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares on a split-adjusted basis.